Black, C. (Corrinda), Cummins, E. (Ewen), Royle, Pamela, Philip, S. and Waugh, Norman. (2007) The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus : a systematic review and economic evaluation. Health Technology Assessment, Vol.11 (No.33). ISSN 1366-5278

Preview	Text WRAP_Waugh_INH mon1133.pdf - Published Version Download (623Kb) | Preview
Preview	Text (Cover sheet) WRAP_waugh11_Coversheet_FinalVersion.pdf Download (166Kb) | Preview

Abstract

Background The two main types of diabetes are type 1 (formerly called insulin-dependent diabetes) and type 2 (formerly called non-insulin-dependent diabetes). In type 1, insulin is always required because the insulin-producing islet cells in the pancreas have been destroyed. In type 2, the pancreas can still produce insulin, and treatment is initially with diet and exercise, but the disease often progresses, with deteriorating control and rising blood glucose levels, and a need next for oral hypoglycaemic agents (OHAs), and later for insulin in about 30%. The aim of insulin therapy is to reduce blood glucose to normal levels, without going too low and causing hypoglycaemia. Insulin currently has to be given by injection. There are various types according to duration of action – short, intermediate and long. Short- and long-acting insulin both come in two forms: traditional and the newer analogues. The traditional form of short-acting insulin is known as soluble. It is given by injection using an insulin pen, or a syringe and needle. Insulin can also be given by continuous subcutaneous infusion by an insulin pump, usually only in selected patients with type 1 diabetes. Objective The aim was to review the clinical effectiveness and cost-effectiveness of a new technology, the inhaled insulin, Exubera® (Pfizer and Sanofi-Aventis in collaboration with Nektar Technologies), a short-acting insulin. Methods A systematic literature review was conducted and economic modelling carried out. Literature searches were done up to November 2005. The industry model, EAGLE, was used for modelling. Results Clinical effectiveness Nine trials of inhaled insulins were found, but only seven used the Exubera form of inhaled insulin. The other two used inhaled insulins that have not yet been licensed. There were five trials in type 1 and two in type 2 diabetes. Inhaled insulin is clinically effective, and is as good as short-acting soluble insulin in controlling blood glucose. The frequency of hypoglycaemia is similar. It works slightly more quickly than soluble insulin. None of the published trials compared it with short-acting analogues, which would have provided a better comparison since they also work slightly more rapidly than soluble. There is also a problem in most of the trials in that patients were on combinations of short-acting, and either long- or intermediate-acting insulin, and both were changed, making it more difficult to assess the effects of only the change from soluble to inhaled insulin. The only significant difference between inhaled and soluble insulin in the trials was in patient preference. Most patients preferred inhaled to injected short-acting insulin, and this has some effect on quality of life measures. However, there could be some bias operating in the trials. The control groups mostly used syringes and needles, rather than pens. As pens are more convenient, their use might have narrowed the patient satisfaction difference. The manufacturer, Pfizer, argues that this patient preference could lead to improved control in some type 1 patients, through improved compliance with treatment, and in some type 2 patients poorly controlled on oral agents, because a switch to insulin therapy would be more acceptable if people could use inhaled rather than injected insulin. These assertions are unproven. There were no trials of inhaled insulin against continuous subcutaneous insulin infusion (CSII). Safety Concern has been raised about the long-term effects of inhaled insulin in the lung. So far, no serious adverse effects have been seen, but until many thousands of people have used inhaled insulin for many years, one cannot rule out some uncommon or rare, but serious, adverse effects. Cost-effectiveness The manufacturer's model (EAGLE) appears to be a high-quality one. However, the results depend more on the assumptions fed into the model than on the model itself. The key assumptions are the size of the gain in quality of life utility from inhaling rather than injecting insulin, the effect of having an inhaled option on the willingness to start insulin among people with poor diabetic control on oral drugs, and the effect on glycaemic control. We consider that the assumptions used in the industry submission make the cost-effectiveness appear better than it really would be. The manufacturer's submission assumed utility gains of 0.036–0.075 in patients with type 1 diabetes, and 0.027–0.067 in those with type 2, based on an unpublished utility elicitation study sponsored by the manufacturer. We thought that these gains were optimistic and that gains of 0.02 or less were more likely, on average. However, patients with particular problems with injection sites might have more to gain, although they might also be a group with much to gain from CSII. A key factor is the cost of inhaled insulin. Much more insulin has to be given by inhaler than by injection, and so the cost of inhaled insulin is much higher than injected. The extra cost depends on dosage, but ranges from around £600 to over £1000 per patient per year. Conclusion The inhaled insulin, Exubera, appears to be effective and safe, but the cost is so much more that it is unlikely to be cost-effective.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Diabetes -- Treatment, Insulin -- Therapeutic use -- Administration, Insulin -- Therapeutic use -- Effectiveness
Journal or Publication Title:	Health Technology Assessment
Publisher:	NIHR Health Technology Assessment programme
ISSN:	1366-5278
Date:	2007
Volume:	Vol.11
Number:	No.33
Status:	Peer Reviewed
Publication Status:	Published
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
References:	1. UKPDS 16. UK Prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995;44:1249–58. 2. National Institute for Clinical Excellence. NICE Clinical Guideline No. 15. Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults. 2004. URL: http://www.nice.org.uk/page.aspx?o=213575. Accessed July 2007. 3. Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med 2002;113:308–16. 4. Cefalu WT. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care 2004; 27:239–46. 5. Diabetes UK. Fact Sheet No. 2. Diabetes: the figures. 2005. URL: http://www.diabetes.org.uk/ infocentre/fact/fact2.htm. Accessed January 2006. 6. National Institute for Clinical Excellence. Full guidance on the use of continuous subcutaneous insulin infusion for diabetes. 2003. URL: http://www.nice.org.uk/page.aspx?o=TA057 guidance. Accessed July 2007. 7. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304–9. 8. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86. 9. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–17. 10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53. 11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405–12. 12. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC–Norfolk). BMJ 2001; 322:15–18. 13. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 (Suppl 1):S15–35. 14. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003;26:881–5. 15. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994;331:1428–36. 16. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986;29:267–74. 17. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965; 14:619–33. 18. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989;321:337–43. 19. Weir GC, Bonner-Weir S. Insulin secretion in non-insulin-dependent diabetes mellitus. In LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes mellitus. Philadelphia, PA: Lippincott, Williams and Wilkins; 2000. pp. 503–8. 20. Leahy JL. Natural history of beta-cell dysfunction in NIDDM. Diabetes Care 1990;13:992–1010. 21. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998;15:290–6. 22. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM 2003; 96:281–8. 23. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330–6. 24. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131:281–303. 25. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17–20. 26. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65. 27. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28:2673–9. 28. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH, Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26:2034–44. 29. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twicedaily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254–9. 30. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260–5. 31. Diabetes Trials Unit. Treating To Target in Type 2 diabetes (4-T) study. 2005. URL: www.dtu.ox.ac.uk/ index.php?maindoc=/4-T/overview.php. Accessed July 2007. 32. National Institute for Clinical Excellence. Algorithm for the management of blood glucose in adults with type 2 diabetes, from Inherited Clinical Guideline G: Management of type 2 diabetes: management of blood glucose. London: NICE; 2002. URL: www.nice.org.uk/ page.aspx?o=36737. Accessed July 2007. 33. Peters J, Stevenson M, Beverley C, Lim JN, Smith S. The clinical effectiveness and costeffectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation. Health Technol Assess 2002;6(5). 34. Rave KM, Nosek L, de la Pena A, Seger M, Ernest CS, Heinemann L, et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005;28:2400–5. 35. Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ 2003;327:383–4. 36. Gonen B, Rubenstein A, Rochman H, Tanega SP, Horwitz DL. Haemoglobin A1: an indicator of the metabolic control of diabetic patients. Lancet 1977; ii:734–7. 37. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1–12. 38. Spitzer WO, Lawrence V, Dales R, Hill G, Archer MC, Clark P, et al. Links between passive smoking and disease: a best-evidence synthesis. A report of the Working Group on Passive Smoking. Clin Invest Med 1990;13:17–42. 39. Khan KS, ter Riet G, Glanville J, Sowden A, Kleijnen J. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out and commissioning reviews. CRD Report 4. 2nd ed. York: Centre for Reviews and Dissemination; 2001. 40. Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002;24:552–64. 41. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001;134:203–7. 42. Cefalu WT. Inhaled insulin: a proof-of-concept study. Ann Intern Med 2001;134:795. 43. Heise T, Tusek C, Stephan JA, Krasner A, Landschulz WH, Sha S, et al. Postprandial glucose control unaffected by insulin antibodies associated with inhaled insulin [poster]. Diabetologia 2004; 47:864. 44. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356–62. 45. Testa MA, Turner RR, Hayes JF, Simonson DC. Patient satisfaction with insulin therapy in type 2 diabetes: a randomized trial of injectable vs. inhaled insulin [abstract]. Diabetes 2002;51:544. 46. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622–7. 47. Su M, Testa MA, Turner RR, Simonson DC. The relationship between regimen burden and psychological well being in persons with type 1 diabetes: inhaled vs injectable insulin [abstract]. Diabetes 2002;51:1843. 48. Testa MA, Turner RR, Hayes JF, Simonson DC. Patient satisfaction and quality of life in type 1 diabetes: a randomized trial of injectable vs. inhaled insulin [abstract]. Diabetes 2001;50:A45. 49. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001; 24:1556–9. 50. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357:331–5. 51. Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630–5. 52. Testa MA, Turner RR, Hayes JF, Simonson DC. Intensive therapy and patient satisfaction in type 1 diabetes: a randomized trial of injected vs. inhaled insulin [abstract]. Diabetologia 2001;44:8. 53. Dumas R, England RD, Riese RJ, Teeter JG. Exubera is well tolerated and achieves tight glycemic control in patients with type 1 diabetes. Diabetes 2005;54:A87. 54. Hermansen K, Ronnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27:162–7. 55. Wollmer P, Clauson P. Evaluation of lung function in patients with type 2 diabetes using the AERx® insulin diabetes management system (iDMS) [abstract]. Diabetes 2003;52:A108. 56. Garg S, Rosenstock J, Muchmore D, De La Pena A, Sun B, Silverman B. Safety and efficacy of preprandial human insulin inhalation powder (HIIP) delivered by the Lilly/Alkermes inhaled insulin system versus injectable insulin in patients with type 1 diabetes (T1D). Diabetes 2005;54:A89. 57. Cappelleri JC, Gerber RA, Kourides IA, Gelfand RA. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. Diabetes Care 2000;23:1799–803. 58. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239–46. 59. Gerber RA, Cappelleri JC, Nadkarni S, Petrie CD, Rosenstock J. Balancing compliance, patient satisfaction and improved glycaemic control in patients with type 1 and type 2 diabetes: longterm studies with inhaled insulin (Exubera® [abstract]. Diabetologia 2002;45:751. 60. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27:1318–23. 61. Rosenstock J. Mealtime rapid-acting inhaled insulin (Exubera®) improves glycemic control in patients with type 2 diabetes failing combination oral agents: a 3-month, randomized, comparative trial [abstract]. Diabetes 2002;51:535. 62. DeFronzo R. Efficacy and safety of inhaled insulin (Exubera®) compared with rosiglitazone in type 2 diabetes patients not optimally controlled on diet and exercise: results of a 3-month, randomized, comparative trial [abstract]. Diabetes 2003;52:A38. 63. Testa MA, Hayes JF, Turner RR, Simonson DC. Quality of life improvements in type 2 diabetes when Exubera is added after failure on metformin monotherapy: an international randomized phase 3 trial [abstract]. Diabetes 2004;53:A437. 64. Testa MA, Turner RR, Hayes JF, Scranton RE, Simonson DC. Satisfaction and quality of life with sulfonylurea plus either metformin or exubera: an international randomized phase 3 trial [abstract]. Diabetes 2004;53:A115. 65. Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH, Inhaled Insulin Phase II Study Group. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 2003;163:2277–82. 66. Barnett A. Efficacy and one-year pulmonary safety of inhaled insulin (Exubera) as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled on oral agent monotherapy [abstract]. Diabetes 2004;53:A107. 67. Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FD, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005;28:427–8. 68. Skyler JS. Long-term, sustained efficacy, and safety of inhaled insulin after 4 years of continuous therapy [abstract]. Diabetologia 2004;47:863. 69. Cefalu WT, Serdarevic-Pehar M. Long-term use of Exubera in type 2 diabetes: observations on glycemic control, pulmonary function and antibody formation [abstract]. Diabetes 2005; 54:A88. 70. Valente AX, Langer R, Stone HA, Edwards DA. Recent advances in the development of an inhaled insulin product. Biodrugs 2003;17:9–17. 71. Himmelmann A, Jendle J, Mellen A, Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care 2003;26:677–82. 72. Henry RR, Mudaliar S, Chu N, Kim D, Armstrong D, Davis TT, et al. Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol 2003;43:1228–34. 73. McElduff A, Mather LE, Kam PC, Clauson P. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin diabetes management system. Br J Clin Pharmacol 2005;59:546–51. 74. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43:781–801. 75. Kim D, Mudaliar S, Chinnapongse S, Chu N, Boies SM, Davis T, et al. Dose–response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care 2003;26:2842–7. 76. Kapitza C, Hompesch M, Scharling B, Heise T. Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol Ther 2004;6:466–72. 77. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002; 4:673–82. 78. Mellen A, Himmelmann A, Jendle J, Wollmer P. Pharmacokinetics and intra-subject variability of inhaled insulin in healthy smokers and nonsmokers. Diabetes 2001;50:A126. 79. Pfutzner A, Mann AE, Steiner SS. Technosphere/insulin – a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002; 4:589–94. 80. Perera AD, Kapitza C, Nosek L, Fishman RS, Shapiro DA, Heise T, et al. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 2002;25:2276–81. 81. White JR, Campbell RK. Inhaled insulin: an overview. Clinical Diabetes 2001;19:13–16. 82. Weerakkody G, Gonzales C, Muchmore D, Chien J. Estimating dose equivalence for new routes of drug administration. J Biopharm Stat 2004;14:1021-36. 83. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. J Clin Endocrinol Metab 2005;90:3287–94. 84. EURODIAB Substudy 2 Study Group. Decreased prevalence of atopic diseases in children with diabetes. J Pediatr 2000;137:470–4. 85. Heinemann L, Traut T, Heise T. Time–action profile of inhaled insulin. Diabet Med 1997; 14:63–72. 86. Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Freemantle N, Mathieu C, et al. Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. Diabetes Technol Ther 2006;8:219–36. 87. Polonsky W, Fisher L, Dowe S, Edelman S. Why do patients resist insulin therapy? [abstract]. Diabetes 2003;52:A417. 88. Polonsky WH, Fisher L, Guzman S, Villa- Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005; 28:2543–5. 89. National Institute for Clinical Excellence. Full guidance on the use of patient-education models for diabetes. 2003. URL: http://www.nice.org.uk/ page.aspx?o=TA060guidance. Accessed July 2007. 90. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:182–8. 91. Skinner TC, Carey ME, Dallosso HM, Davies MJ, Heller S, Khunti K, et al. Illness beliefs and prevalence of depression at diagnosis in individuals with type 2 diabetes: baseline results from the DESMOND randomised controlled trials. Diabet Med 2007;24(Suppl 1):A56. 92. UK Prospective Diabetes Study (UKPDS) 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 1990;13:1–11. 93. Gerber RA, Hauber AB, Bolinder B, Johnson FR. Diabetes patients’ stated preference for insulin therapies: trading health for convenience [abstract]. Diabetologia 2004;47:755. Additional information kindly provided by Pfizer in form of poster. 94. Hauber AB, Johnson FR, Sauriol L, Lescrauwaet B. Risking health to avoid injections: stated preferences of Canadians with diabetes [poster]. Diabetologia 2004;47:761. 95. Dolan P, Roberts J. Modelling valuations for EQ-5D health states: an alternative model using differences in valuations. Med Care 2002;40:442–6. 96. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108. 97. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002; 25:2238–43. 98. Bagust A, Beale S. Modelling EuroQol healthrelated utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217–30. 99. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002;25:458–63. 100. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340–9. 101. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124:136–45. 102. Acharya S, Philip S, Viswanath AK, Waugh NR, Pearson DWM. Body mass index and glycaemic control in late-adolescents and young adults with type 1 diabetes mellitus. Diabetes UK, Annual Professional Conference. 29–31 March 2006, Birmingham, UK. 103. DeVries JH. Mealtime inhaled insulin lowers fasting glucose: a look at possible explanations. Diabetologia 2005;48:1–2. 104. National Research Register (Department of Health). Exubera Real World Classic. 2005. URL: http://www.nrr.nhs.uk/ViewDocument.asp?ID= N0217155973. Accessed July 2007. 105. Insulin inhalation – Pfizer/Nektar Therapeutics: HMR 4006, inhaled PEG-insulin–Nektar, PEGylated insulin–Nektar. Drugs R D 2004; 5:166–70. 106. Medical News Today. Phase 3 safety study for inhaled insulin – Lilly and Alkermes. 2005. URL: http://www.medicalnewstoday.com/medicalnews.php? newsid=28004. Accessed July 2007. 107. Leach C, Kuo MC, Perkins K, Bueche B, Guo LH, Bentley M, et al. Dry powder formulation of inhaled PEG-insulin yields prolonged systemic activity in dogs [abstract]. Diabetes 2003; 52:A105–6. 108. Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol Ther 2004;6:510–17. 109. Gordon Still J. Development of oral insulin: progress and current status. Diabetes Metab Res Rev 2002;18:S29–37. 110. Modi P, Mihic M, Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist™ system. Diabetes Metab Res Rev 2002;18:S38–42. 111. Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Dose–response relationship of oral insulin spray in healthy subjects. Diabetes Care 2005; 28:1353–7. 112. Gomez-Perez FJ, Rull JA. Insulin therapy: current alternatives. Arch Med Res 2005;36:258–72. 113. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49:1711–21. 114. Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004;CD003418. 115. Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med 2005;22:634–40. 116. Strowig SM, Raskin P. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes Obes Metab 2005;7:633–41. 117. Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005;7:675–91. 118. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736–42. 119. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 1997;278:1663–9. 120. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999;130:389–96. 121. Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study. Diabet Med 2005; 22:316–22. 122. Aas AM, Seljeflot I, Torjesen PA, Diep LM, Thorsby PM, Birkeland KI. Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes. Diabetologia 2006;49:872–80. 123. Schuyler MR, Niewoehner DE, Inkley SR, Kohn R. Abnormal lung elasticity in juvenile diabetes mellitus. Am Rev Respir Dis 1976;113: 37–41. 124. Schernthaner G, Haber P, Kummer F, Ludwig H. Lung elasticity in juvenile-onset diabetes mellitus. Am Rev Respir Dis 1977;116:544–6. 125. Sandler M, Bunn AE, Stewart RI. Pulmonary function in young insulin-dependent diabetic subjects. Chest 1986;90:670–5. 126. Kodolova IM, Lysenko LV. Morphological changes in the lung blood vessels in diabetes mellitus. Arkh Patol 1979;41:31–6. 127. Vracko R, Thorning D, Huang TW. Basal lamina of alveolar epithelium and capillaries: quantitative changes with aging and in diabetes mellitus. Am Rev Respir Dis 1979;120:973–83. 128. Weynand B, Jonckheere A, Frans A, Rahier J. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration 1999; 66:14–19. 129. Farina J, Furio V, Fernandez-Acenero MJ, Muzas MA. Nodular fibrosis of the lung in diabetes mellitus. Virchows Archiv 1995;427:61–3. 130. Kodolova IM, Lysenko LV, Saltykov BB. Changes in the lungs in diabetes mellitus. Arkh Patol 1982;44:35–40. 131. Vracko R, Pecoraro RE, Carter WB. Overview article: basal lamina of epidermis, muscle fibers, muscle capillaries, and renal tubules: changes with aging and in diabetes mellitus. Ultrastruct Pathol 1980;1:559–74. 132. Watanabe K, Senju S, Toyoshima H, Yoshida M. Thickness of the basement membrane of bronchial epithelial cells in lung diseases as determined by transbronchial biopsy. Respir Med 1997;91: 406–10. 133. Kida K, Utsuyama M, Takizawa T, Thurlbeck WM. Changes in lung morphologic features and elasticity caused by streptozotocin-induced diabetes mellitus in growing rats. Am Rev Respir Dis 1983;128:125–31. 134. Popov D, Simionescu M. Alterations of lung structure in experimental diabetes, and diabetes associated with hyperlipidaemia in hamsters. Eur Respir J 1997;10:1850–8. 135. Mompeo B, Popov D, Sima A, Constantinescu E, Simionescu M. Diabetes-induced structural changes of venous and arterial endothelium and smooth muscle cells. J Submicrosc Cytol Pathol 1998;30:475–84. 136. Plopper CG, Morishige WK. Alterations in the ultrastructure of nonciliated bronchiolar epithelial (Clara) cells by streptozotocin-induced diabetes in rats. Am Rev Respir Dis 1979;120:1137–43. 137. Popov D, Hasu M, Costache G, Stern D, Simionescu M. Capillary and aortic endothelia interact in situ with nonenzymatically glycated albumin and develop specific alterations in early experimental diabetes. Acta Diabetol 1997; 34:285–93. 138. Asanuma Y, Fujiya S, Ide H, Agishi Y. Characteristics of pulmonary function in patients with diabetes mellitus. Diabetes Res Clin Pract 1985;1:95–101. 139. Bell D, Collier A, Matthews DM, Cooksey EJ, McHardy GJ, Clarke BF. Are reduced lung volumes in IDDM due to defect in connective tissue? Diabetes 1988;37:829–31. 140. Innocenti F, Fabbri A, Anichini R, Tuci S, Pettina G, Vannucci F, et al. Indications of reduced pulmonary function in type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract 1994; 25:161–8. 141. Primhak RA, Whincup G, Tsanakas JN, Milner RD. Reduced vital capacity in insulindependent diabetes. Diabetes 1987;36:324–6. 142. Schnack C, Festa A, Schwarzmaier-D’Assie A, Haber P, Schernthaner G. Pulmonary dysfunction in type 1 diabetes in relation to metabolic longterm control and to incipient diabetic nephropathy. Nephron 1996;74:395–400. 143. Strojek K, Ziora D, Sroczynski JW, Oklek K. Pulmonary complications of type 1 (insulindependent) diabetic patients. Diabetologia 1992;35:1173–6. 144. Maccioni FJ, Colebatch HJ. Lung volume and distensibility in insulin-dependent diabetes mellitus. Am Rev Respir Dis 1991;143:1253–6. 145. Ozmen B, Celik P, Yorgancioglu A, Ozmen B, Ozmen D, Cok G. Pulmonary function parameters in patients with diabetes mellitus. Diabetes Res Clin Pract 2002;57:209–11. 146. Benbassat CA, Stern E, Kramer M, Lebzelter J, Blum I, Fink G. Pulmonary function in patients with diabetes mellitus. Am J Med Sci 2001; 322:127–32. 147. Mori H, Okubo M, Okamura M, Yamane K, Kado S, Egusa G, et al. Abnormalities of pulmonary function in patients with non-insulindependent diabetes mellitus. Intern Med 1992; 31:189–93. 148. Cooper BG, Taylor R, Alberti KG, Gibson GJ. Lung function in patients with diabetes mellitus. Respir Med 1990;84:235–9. 149. Heimer D, Brami J, Lieberman D, Bark H. Respiratory muscle performance in patients with type 1 diabetes. Diabet Med 1990;7:434–7. 150. Matsubara T, Hara F. The pulmonary function and histopathological studies of the lung in diabetes mellitus. Nippon Ika Daigaku Zasshi 1991; 58:528–36. 151. Niranjan V, McBrayer DG, Ramirez LC, Raskin P, Hsia CC. Glycemic control and cardiopulmonary function in patients with insulin-dependent diabetes mellitus. Am J Med 1997;103:504–13. 152. Sandler M, Bunn AE, Stewart RI. Cross-section study of pulmonary function in patients with insulin-dependent diabetes mellitus. Am Rev Respir Dis 1987;135:223–9. 153. Guvener N, Tutuncu NB, Akcay S, Eyuboglu F, Gokcel A. Alveolar gas exchange in patients with type 2 diabetes mellitus. Endocr J 2003;50:663–7. 154. Marvisi M, Bartolini L, del Borrello P, Brianti M, Marani G, Guariglia A, et al. Pulmonary function in non-insulin-dependent diabetes mellitus. Respiration 2001;68:268–72. 155. Ramirez LC, Dal Nogare A, Hsia C, Arauz C, Butt I, Strowig SM, et al. Relationship between diabetes control and pulmonary function in insulin-dependent diabetes mellitus. Am J Med 1991;91:371–6. 156. Minette P, Buysschaert M, Rahier J, Veriter C, Frans A. Pulmonary gas exchange in life-long nonsmoking patients with diabetes mellitus. Respiration 1999;66:20–4. 157. Fuso L, Cotroneo P, Basso S, De Rosa M, Manto A, Ghirlanda G, et al. Postural variations of pulmonary diffusing capacity in insulin-dependent diabetes mellitus. Chest 1996;110:1009–13. 158. Lange P, Groth S, Kastrup J, Mortensen J, Appleyard M, Nyboe J, et al. Diabetes mellitus, plasma glucose and lung function in a crosssectional population study. Eur Respir J 1989; 2:14–9. 159. Lange P, Groth S, Mortensen J, Appleyard M, Nyboe J, Schnohr P, et al. Diabetes mellitus and ventilatory capacity: a five year follow-up study. Eur Respir J 1990;3:288–92. 160. Walter RE, Beiser A, Givelber RJ, O’Connor GT, Gottlieb DJ. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med 2003;167:911–16. 161. Enright PL, Kronmal RA, Higgins M, Schenker M, Haponik EF. Spirometry reference values for women and men 65 to 85 years of age. Cardiovascular health study. Am Rev Respir Dis 1993;147:125–33. 162. Engstrom G, Janzon L. Risk of developing diabetes is inversely related to lung function: a population-based cohort study. Diabet Med 2002;19:167–70. 163. Barrett-Connor E, Frette C. NIDDM, impaired glucose tolerance, and pulmonary function in older adults. The Rancho Bernardo Study. Diabetes Care 1996;19:1441–4. 164. Davis T, Edelman SV. Insulin therapy in type 2 diabetes. Med Clin North Am 2004;88:865–95. 165. Davis TM, Knuiman M, Kendall P, Vu H, Davis WA. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2000; 50:153–9. 166. Klein BE, Moss SE, Klein R, Cruickshanks KJ. Is peak expiratory flow rate a predictor of complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. J Diabetes Complications 2001;15:301–6. 167. Klein BE, Moss SE, Klein R, Cruickshanks KJ, Wisconsin Epidemiologic Study of Diabetic Retinopathy. Peak expiratory flow rate: relationship to risk variables and mortality: the Wisconsin Epidemiologic Study of diabetic retinopathy. Diabetes Care 2001;24:1967–71. 168. Bergenstal R. Efficacy and safety of inhaled insulin (Exubera®) compared with rosiglitazone in type 2 diabetes patients not optimally controlled on diet and exercise: results of a 3-month, randomised, comparative trial [abstract]. Diabetologia 2003; 46:801. 169. Bergenstal R. Achieving target HbAIC in studies with inhaled insulin in type 2 diabetes [poster]. Diabetologia 2004;47:866. 170. Cefalu WT. Mealtime rapid-acting inhaled insulin (Exubera) improves glycaemic control in patients with type 2 diabetes failing combination oral agents: a 3-month, randomised, comparative trial [abstract]. Diabetologia 2002;45:807. 171. DeFronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005;28:1922–8. 172. Simonson DC, Turner RR, Hayes JF, Scranton RE, Testa MA. Improving quality of life in type 2 diabetes when Exubera® is added after failure on metformin: a multicenter, international trial [abstract]. Diabetologia 2004;47:865. 173. Testa MA, Turner RR, Hayes JF, Scranton RE, Simonson DC. An international trial of sulfonylurea plus either metformin or Exubera®: impact on quality of life and treatment satisfaction [abstract]. Diabetologia 2004;47:9. 174. Department of Health. NHS reference costs 2004, Appendix 4. London: Department of Health; 2005. 175. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20:442–50. 176. Joint Formulary Committee. British National Formulary, 49th edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2005. 177. Gordois A, Scuffham P, Shearer A, Oglesby A. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 2004;18:18–26. 178. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26:1790–5. 179. Joint Formulary Committee. British National Formulary, 51st edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2006.
URI:	http://wrap.warwick.ac.uk/id/eprint/52139

Request changes to a record

Actions (login required)

View Item